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We aimed to determine the proportion of “fit” versus “vulnerable” older patients with cancer included 
in phase II and III oncology registration trials, as compared to the proportions in a real life oncology 
setting. 
Methods  
Trial and patient characteristics of older (≥70 years) patients treated at the OECI-designated clinical 
cancer centre in Kortrijk and included in a phase II or III oncology registration trial were collected 
retrospectively. These patients were matched individually with randomly-selected patients from the 
general oncology setting, based on gender, age, tumour type, tumour stage, and treatment intent. 
Patients’ fitness, based on routine Geriatric-8 (G8) screening, was retrieved from prospectively 
constructed databases. 
Results 
Between November 2012 and October 2018, 218 older patients with cancer were included in a phase II 
or III oncology registration trial. Of those, 41 cases with a mean age of 76,0 years were included in the 
analyses. A Fisher’s Exact Test revealed a statistical significant difference between cases and matched 
controls, with a higher proportion of “fit” patients included in phase II or III oncology registration trials 
compared to the proportion in the matched control group (respectively 70.7% and 41.5%, p<0.010). 
Discussion 
We provide evidence for the hypothesis that older patients included in phase II or III oncology trials are 
significantly fitter than the real life oncology population. Some form of geriatric evaluation should be 
integrated in future cancer clinical trials to enable stratification according to this parameter and allow 




With the current demographic revolution, a result of the ageing of populations, epidemiologic data have 
predicted that the cancer incidence in older (≥ 65 years) adults will increase with 67% by 2030 in the 
United States.1 Despite the continued increase in cancer incidence in older individuals, data from large 
cooperative groups have shown that only 22 to 32% of the older patient population participates in trials 
for cancer therapy.2-4 However, the majority of older adults enrolled on clinical trials have a good Eastern 
Cooperative Oncology Group Performance Status (ECOG PS) which makes them not representative for 
the majority of patients seen in the clinic. The oncogeriatric population is very heterogeneous, and based 
on their general health status they can be categorized as “fit”, “vulnerable”, or “frail”, which respectively 
corresponds to functionally independent patients, those with increased risk of developing dependency, 
and those who have a minimal functional reserve.5-7 
Phase II and III registration trials are designed for the approval of new drug applications (NDA) or 
supplemental new drug applications (sNDA) for the extension of indications and/or posology. As the 
inclusion and exclusion criteria are very strict, usually only fit older patients can be enrolled8, limiting 
the applicability of evidence-based recommendations within the field of oncology to older patients with 
cancer who may have a vulnerable or frail profile.9,10 In geriatric oncology, clinical judgement alone is 
not sufficient for optimal treatment planning. Before its initiation, oncologists must be aware of age-
related changes and identify the subset of patients who are vulnerable and at risk of increased treatment 
toxicity in order to ensure effective and safe cancer treatment in this patient population.11-13 
The National Comprehensive Cancer Network (NCCN), the International Society of Geriatric Oncology 
(SIOG) and the American Society of Clinical Oncology (ASCO) recommend a geriatric evaluation of 
all patients with cancer aged 65 years and older.14-16 They suggest a two-step method consisting of a 
short screening tool to select patients who need further multidisciplinary evaluation to guide treatment-
related decisions as well as to implement geriatric interventions.14,17-20 In the General Hospital 
Groeninge, we opt for the Geriatric-8 (G8) as a first step screening tool to identify older patients with 
cancer who would benefit from a more in-depth evaluation. The latter, also referred to as a 
comprehensive geriatric assessment (CGA), represents the second step. The G8 alone, however, appears 
to be predictive for functional decline and overall survival.21-23 Older adults with cancer, characterized 
as fit from this screening, are assumed to benefit from the same treatment as younger patients. If these 
patients could be separated from those that would not benefit or even have a detrimental effect of 
treatment, treatment side effects and survival loss could be decreased in the latter population. The CGA 
is a comprehensive measure to recognize heterogeneity among older adults and to characterize the 
“functional age” of an older patient, allowing individualized approaches for cancer treatment. 
Furthermore, it detects unsuspected conditions in more than 50% of patients older than 65 years that 
may affect their ability to complete cancer treatment.24-26 
Over the past few years, Dr. Arti Hurria advocated for the accrual of (vulnerable) older patients with 
cancer in clinical trials to improve the evidence base for treatments in this growing population.27-30 Her 
research topics related to older adults with cancer and the use of a geriatric assessment (GA) had a 
considerable influence on our research perspectives. The past years, many academic studies on the 
clinical relevance of a CGA were carried out by our research group.31-34 
At present, no data have been published concerning the proportion of fit versus vulnerable/frail older 
patients with cancer included in a clinical trial in a general hospital setting, compared to the real life 
population of older patients with cancer. Therefore, our aim was to evaluate these proportions of G8-






2.1. Study population and design 
Patients were recruited upon presentation at the Kortrijk Geriatric Oncology Clinic. The General 
Hospital Groeninge is a 1054-bed non-for-profit public-private partnership (PPP) teaching hospital. 
Eligible patients needed to be ≥70 years at the time of trial inclusion, be diagnosed with a histologically 
confirmed solid tumour or haematological malignancy (any stage and any type of treatment), be included 
in a phase II or III oncology registration trial at the Organisation of European Cancer Institutes (OECI)-
designated clinical cancer centre of the General Hospital Groeninge, Kortrijk, Belgium, and have been 
evaluated with the G8 screening tool or full CGA. All geriatric data needed to be collected within six 
months from trial inclusion. Patients included in elderly-specific phase II or III oncology registration 
trials were excluded. The online Appendix A summarizes the phase II/III trials included in analysis and 
their characteristics. 
Patients recruited in phase II or III oncology registration trials were named ‘cases’ and have been 
matched to older patients from the general oncology setting included in the oncogeriatric database from 
the General Hospital Groeninge, further referred to as ‘matched controls’. Cases and controls were 
matched if they were equal on following five criteria: gender, age, tumour type, tumour stage, and 
treatment intent. The research associate (L.T.) was not informed about their G8 (and CGA) result. If 
there was no match available in the database that fulfilled the matching criteria, cases were excluded 
from analysis. 
The hypothesis of this study was formulated prospectively. Ethical approval was obtained by the local 
ethics committee of the General Hospital Groeninge (AZGS2015023). Formerly, the ethics committee 
approved registration of demographic, oncology and geriatric parameters within the framework of the 
KPC_24_A_025 (AZGS2012057), PROACTIVE (AZGS2012061), and REGERCAN (AZGS2015081) 
trials. These data have been retrospectively analysed within the scope of this research and have been 
registered without written consent in the oncogeriatric database since G8 and/or CGA are routine 
practice at our hospital (online Appendix B: Care Model Geriatric Oncology General Hospital 
Groeninge). Between November 2012 and October 2018, a mean of 65.6%  of oncogeriatric patients 
with diagnosis and treatment at our hospital have received a GA (minimum coverage of 39.4% , 
maximum coverage of 73.3%).  
2.2. Measures  
Three onco-psychologists (L.K., J.D.Z., E.M.) and two research associates (L.P., M.L.) were qualified 
to conduct the G8 and/or CGA and are called trained healthcare workers (THCWs). Since G8 screening 
data are available for all patients, we defined patients with a G8 score of more than 14 as G8-negative 
(G8-) or fit and those who scored 14 or less as G8-positive (G8+) or vulnerable.18,22,23,35 
In case of a positive screening (G8 ≤14), a full CGA was conducted. The CGA examines different age-
related domains including comorbidities (Charlson Comorbidity Index (CCI)36), polypharmacy (number 
of drugs), functional status (Activities of Daily Living (ADL), instrumental Activities of Daily Living 
(iADL)37,38), cognition (mini-mental status examination (MMSE) or Freund Clock Drawing Test 
(CDT)39,40), nutrition (Mini Nutritional Assessment - Short Form41), emotional status (Geriatric 
Depression scale – 1542) and physical status (number of falls). When one reaches the cut-off value of a 
certain CGA domain, this patient is suggested to be ‘vulnerable’ on that specific domain. Two 
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definitions of vulnerability based upon CGA result were used: vulnerability in one or more domains and 
vulnerability in two or more domains.35,43 
2.3. Statistical analysis 
Descriptive statistics were performed to present patient and trial characteristics. In order to assess the 
comparability of both cohorts, also demographic and clinical data were statistically analysed by using 
an independent sample t-test or Exact Pearson Chi-Square test. The proportions of G8- and G8+ patients 
were assessed by a 2x2 Contingency table to determine the association between the two variables 
condition (G8-/G8+) and group (case/matched control). A Fisher’s Exact test was used to compare the 
proportions of G8+ patients in the group of cases, matched controls and older patients with cancer 
included in the oncogeriatric database at the General Hospital Groeninge. P-values below 0.05 were 
considered statistically significant. All statistical analyses were conducted using Microsoft Office Excel 
2013 (Microsoft, Inc., Redmond, WA) and IBM SPSS v.24 (SPSS, Inc., Chicago, IL) software. 
 
3. Results 
3.1. Study population characteristics 
From November 2012 till October 2018, 3,017 older patients with cancer were evaluated by a G8 
screening and/or CGA in the Kortrijk Geriatric Oncology Clinic. Within the same period, 688 patients 
had been included in phase II or III oncology registration trials. Of those, 380 patients were excluded as 
they were not 70 years or older, and another 116 patients had a protocol-specific screen failure for the 
respective trials. Next, another 170 were excluded as the G8 was not assessed (N=122) or not within six 
months from trial inclusion (N=48), five were part of an elderly-specific trial, and for two patients no 
match was possible. The remaining 41 cases were eligible for analysis (Fig. 1). Of all 41 patients, 18 
had a geriatric evaluation before trial inclusion (median time 22 days), 4 had an assessment on the 
moment of trial inclusion, and 19 had an evaluation after they were included in a phase II or III clinical 
trial (median time 89 days). 
Fig. 1. Patient flow diagram. 
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Cases had an average age of 76.0 years and matched controls had an average of 75.0 years (range for 
both cohorts: 70-86 years). The selected cohorts included more male than female individuals (75.6% 
and 24.4%, respectively). Within the case cohort, more patients were married in comparison to the 
control group (80.5% and 68.3%, respectively), but the living situation was similar in both cohorts with 
≥95.0% living at home. Professional homecare was used more by matched controls than by the cases 
(58.5% and 39%, respectively). Patients included in phase II or III oncology registration trials were 
diagnosed with the following malignant conditions: genitourinary (39.1%), haematological 
malignancies (34.1%), digestive tract (12.2%), gynaecological (9.7%), and breast (4.9%). Most tumours 
were advanced (51.2%) and a treatment with palliative intent was assigned to a majority of patients 
(58.5%). Full demographic and oncology characteristics of the cases and matched controls are presented 





3.2. Trial characteristics 
As illustrated in table 2, there were less phase II than phase III oncology registration trials included in 
this retrospective study (39.3% and 60.7%, respectively). Also, most of the trials were commercial 
(71.4%). The clinical specialty groups of the trials included in our analysis were genitourinary tumours 
(35.7%), haematological malignancies (32.1%), digestive oncology (14.3%), gynaecological 
malignancies (7.1%), and breast cancer (7.1%). Targeted therapy alone and in combination with 
Table 1. Demographic and oncology characteristics of Cases and Matched controls  





































p = 1.00 
Age, y 
Mean (range) 76.0 (70-86) 75.0 (70-86) p = 0.98 
Education: age, y 
Mean (range) 17.1 (13.5-23) 16.9 (13-23) p = 0.76 
Marital Status 
Married                             
Widow-er                              




























p = 0.41* 
Living situation 
Home with partner                           
Home – alone                              










































p = 0.08 
Primary tumour diagnosis 
Breast 
Digestive  
Genitourinary – bladder 
Genitourinary – prostate 
Gynaecological – ovary and primary peritoneal carcinoma 
Gynaecological – corpus uteri 
Gynaecological – other 
Haematological – non-hodgkin lymphoma 












































































































p = 1.00* 
*The assumption for Chi-square Test that no more than 20% of the expected counts may be less than 5 and all individual expected counts 





chemotherapy were the most common types of investigational therapy (35.7% and 17.9%, respectively). 
Targeted therapy included monoclonal antibodies (e.g. Rituximab), PARP inhibitors (e.g. niraparib), 
FGFR inhibitors (e.g. pemigatinib), tyrosine kinase inhibitors (e.g. ibrutinib), and CDK inhibitors (e.g. 
ribociclib). More information on the phase II/III oncology registration trials included in analysis can be 
found in the online Appendix A. 
 
 
3.3. Comparison of the proportion of vulnerable older patients in phase II or III oncology registration 
trials compared to the proportion in the general oncology setting 
As presented in figure 2, 29 cases and 17 matched control patients were categorized as G8- (70.7% and 
41.5%, respectively) while 12 cases and 24 matched controls were judged as G8+ (29.3% and 58.5%, 
respectively). A contingency table was created to assess the association between the two variables, 
condition (G8-/G8+) and group (case/control). A two-tailed Fisher’s Exact test indicated a significant 
difference between the proportions G8- and G8+ older patients with cancer in the case and matched 
control group (p<0.05), as well as between the proportions in the case group and oncogeriatric database 
(p<0.001). 
The proportions of G8- and G8+ patients in the matched control group resembled the proportions of G8- 
(43.9%) and G8+ (56.1%) older patients with cancer who had a geriatric screening between November 




Fig. 2. Proportions of G8- and G8+ older patients with cancer in the group with cases, matched 
controls and patients included in the oncogeriatric database from the General Hospital Groeninge (*), 
determined by G8 score. 
3.4. Determination of the CGA domains in which geriatric vulnerabilities are most frequently detected 
Of all patients included, 29.3% of the cases (12/41) and 58.5% of the matched controls (24/41) had a 
positive G8 screening. Consequently, THCWs performed a CGA. Although not all CGA data were 
complete, abnormal test results of the G8+ patients in the groups of cases, matched controls and older 
patients with cancer included in the oncogeriatric database were most frequently detected in the domains 
of community functioning (58.3%, 75.0%, and 84.5%, respectively), nutrition (58.3%, 65.2%, and 
72.6%, respectively), and polypharmacy (75.0%, 70.8%, and 69.7%, respectively). Based on the results 
of the CDT screening tool, G8+ cases showed a trend to score negative on the cognitive domain, in 
contrast to the control groups. However, all G8+ cases and matched controls scored negative on the 




The CGA conducted in G8+ patients enables the identification of vulnerable and frail profiles. In table 
4, three categories within G8+ groups are displayed: vulnerable patients with a G8 score ≤14, those with 
a G8 score ≤14 and vulnerable in at least one domain of the CGA, and, last, patients with a G8 score 
≤14 and vulnerability in at least two CGA domains. A two-tailed Fisher’s Exact test revealed a 
significant difference between cases and matched controls for first two categories (p<0.05), but not for 
the last category (p=0.064). Still, the number of G8+ cases was significantly different from the older 
patients with cancer included in the oncogeriatric database for all three categories (p<0.001). There was 
no significant difference observed between the matched controls and the patients included in the 




Table 3. CGA domains of G8+ Cases, Matched controls and the oncogeriatric population of the General Hospital Groeninge(*) 
 
Test Range Cut-off 
No. of  
G8+ Cases 
(N=12**) % 
No. of G8+ 
Matched controls 
(N=24**) % 
No. of G8+  
older patients  
with cancer* 
(N=1693**) % 
Functional status –  
self care 
ADL 0-6 ≤ 5 0/12 
0.0 
0/24 0.0 907/1668 54.4 
Functional status – 
community functioning 
iADL 0-8 ≤ 7 7/12 
58.3 
18/24 75.0 1408/1666 84.5 
Physical status No. of falls NA ≥1 3/12 
25.0 
5/23 21.7 594/1662 35.7 
Cognition MMSE 0-30 ≤ 23 0/6 
0.0 
0/12 0.0 239/734 32.6 
 CDT 0-7 ≤ 4 0/5 
0.0 
5/13 38.5 233/804 29.0 
Depression GDS-15 0-15 ≥ 6 2/10 
20.0 
2/20 10.0 230/1293 17.8 
Nutrition MNA-SF 0-14 ≤ 11 7/12 
58.3 
15/23 65.2 1214/1673 72.6 
Co-morbidities CCI 0-37 ≥ 4 2/12 
16.7 
0/24 0.0 453/1693 26.8 
Polypharmacy No. of 
drugs 
NA ≥5 9/12  
75.0 
17/24 70.8 1180/1692 69.7 
* patients included in the oncogeriatric database at the General Hospital Groeninge (November 2012 - October 2018) 
** number of vulnerable patients included in the cohort (not all CGA domains were completed) 
Abbreviations: ADL: Activities of Daily Living, iADL: instrumental Activities of Daily Living, MMSE: Mini Mental State Examination, CDT: 
Clock Drawing Test, GDS-15: 15-item Geriatric Depression Scale, MNA-SF: Mini Nutritional Assessment-Short Form, CCI: Charlson Comorbidity 





This paper aimed at identifying the proportion of G8+ older patients with cancer included in phase II/III 
oncology registration trials, compared to the proportion in a real life oncology setting. In this 
retrospective case-control study, at least 70% of older patients with cancer were designated fit by the 
G8 screening tool within six months from participation to a phase II or III oncology registration trial. 
This number is significantly different from the proportion of G8- older patients with cancer in the 
matched control group, as well as from the patients included in the oncogeriatric database. These data 
highlight the underrepresentation of vulnerable/frail older patients with cancer in phase II/III clinical 
trials. 
The low recruitment of (vulnerable) older patients with cancer in clinical trials can be explained by strict 
eligibility criteria such as the ECOG PS and the exclusion of patients who are cognitively impaired.2-
4,44,45 Studies have revealed that most older patients with cancer would forgo a potentially life-saving 
treatment if it impacted function or cognition.46,47 In our retrospective analysis, not all CGA data were 
complete and results on the cognitive domain should be interpreted cautiously as only half of the G8+ 
cases and G8+ matched controls fulfilled the CDT and MMSE. To allow a correct interpretation of table 
3, absolute values of the number of G8+ cases, G8+ matched controls and G8+ older patients with cancer 
are indicated. Based on the results of the Freund CDT screening tool, the vulnerable patients included 
in phase II/III oncology registration trials seem to show a trend towards good cognitive functioning9,48, 
especially in comparison with the matched controls and patients included in the oncogeriatric database. 
When participating to a clinical trial, more support is mandatory in case of reduced cognitive functioning 
as it is essential one understands the trial and therapy side effects. Also, the majority of patients included 
in this study were treated with palliative intent. If these patients with an already vulnerable or frail profile 
would be forced into a curative treatment setting, they might suffer from symptoms not only caused by 
cancer, but also by treatment-induced toxicity. This points out the lack of evidence-based data related 
to the benefits and risks of cancer treatment in the vulnerable older patient as mainly older patients with 
a fit profile are enrolled in clinical oncology trials.49 
Indeed, the evidence base concerning the effectiveness of treatment and potentially adverse 
consequences among older and/or frail adults remains sparse. Adaptation of trial designs to allow more 
vulnerable patients to receive upfront dose reductions or less intense regimens could be a useful 
intervention as treatment prescriptions for older adults with cancer are largely based on evidence 
generated in younger or fitter older adults. Therefore, Hurria et al. suggested an extension of patent 
exclusivity and post approval evaluation to administer effective and safe curative cancer treatment for 
older adults with cancer.50 In 2014, we introduced the concept of a dose-expansion cohort (DEC) 
dedicated in vulnerable older patients to be incorporated in phase 1b/2a protocols.51 A DEC offers the 
opportunity to reassess the efficacy, toxicity and maximally tolerated dose in these patients in the early 
phases of drug development. This modification of clinical trials for older patients was seconded by Dr. 
Arti Hurria, who was in favour of adding a cohort of older patients with cancer to the treatment arm that 
was shown to be superior, in order to evaluate the tolerability in older adults.28,52 
Another adaptation of trials concerns the standard end-points such as disease-free survival or response 
rate (respectively in curative/adjuvant and palliative setting). For older adults with cancer, these are less 
applicable as they often die from other causes than the disease itself or from relapse. As daily functioning 
could offer a more accurate illustration of treatment outcome, it is suggested to integrate CGA 
parameters as surrogate trial end-points for older adults. Evaluation of geriatric parameters could 
contribute to better understanding the impact of new therapies on older individuals with cancer and to 
improving care in this vulnerable population.49,53 This case-control study advocates for the application 
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of a GA before treatment start as it offers a correct estimation of an older person’s treatment tolerance 
and possible benefit. 
In this study, we investigated in which CGA domains the two separate cohorts of G8+ cases and matched 
controls most often reached the assigned cut-off values. Community functioning (iADL), nutrition and 
polypharmacy appeared as most sensitive CGA domains. This outcome acknowledges previous 
literature pointing out iADL and nutritional status as strong individual prognostic factors for overall 
survival in patients with cancer.18,54 Ideally, this outcome should be confirmed with a multicentre 
prospective cohort study. 
To date, there is no consensus on a definition of frailty for oncology trials. Definitions in the general 
geriatric population are not specifically for older adults with cancer limiting their applicability. In this 
study, iADL, nutrition and polypharmacy were the CGA domains on which most G8+ patients reached 
the threshold, but it is plausible to consider other commonly applied criteria for the classification of 
patients as fit, vulnerable or frail. The EORTC Minimal Dataset interprets ≥1 dependency in G8, iADL, 
CCI, and Social Situation as vulnerability20,49, while the NCCN older adult oncology guidelines judge 
elderly as vulnerable if they are ADL and/or iADL positive and as frail if they appear vulnerable on 
ADL, iADL, CCI, and/or physical, nutritional, affective, and cognitive domain.14 For Droz et al. (2010), 
significant comorbidity, iADL dependence, and severe malnutrition are the criteria to judge one 
vulnerable or frail, depending on the grade of comorbidity.55 
According to Hamaker et al. (2012), an older patient with cancer is considered vulnerable when 
impairment is detected in at least two CGA domains35, while Soubeyran et al. (2011) used a less stringent 
definition as dependence in at least one domain is sufficient.43 As indicated in table 4, there is only a 
small difference between older patients who are G8+ only and those who are G8+ and vulnerable in one 
or two CGA domains, and our conclusions remain the same regardless of the definition used. The easiest 
way to define vulnerability is a G8 score of 14 or less. In our hospital, THCWs conduct a full CGA in 
G8+ patients, or on specific request of the physician. Regarding the clinical significance of a CGA, the 
appropriate judgement of THCWs is crucial to identify vulnerable or frail patients. The number of 
positive CGA domains to define frailty remains undetermined in geriatric oncology. For future research, 
we will keep track of which domains could be decisive in order to define frailty. 
Some considerations need to be made when interpreting these results. First, this case-control study was 
monocentric and only patients included in phase II or III clinical trials that took place in the General 
Hospital Groeninge were selected. Second, the analysed sample size is relatively small due to the 
(strong) inclusion and exclusion criteria and the retrospective nature of this study. Although G8 
screening and CGA are routine practice at our cancer centre, not all data were complete or gathered 
within six months from trial inclusion. Additionally, we were unable to match two patients according to 
the five matching criteria (age, gender, tumour type, tumour stage and treatment intent). Third, the 
selection of phase II/III trials might not be a convenient representation for the oncology registration 
trials in a real life oncology setting. For example, breast cancer is far more frequent than gynaecological 
tumours, but in this case-control study, results showed the opposite. This can be explained by trials’ 
availability to include patients and, again, the strict inclusion criterion of a G8 result available within 
six months from trial inclusion. At last, 75% of patients included in analysis were male. This 
underrepresentation of women in our analysis can be largely explained by the imbalance in trials. When 
six patients were confronted with breast or gynaecological malignant condition, there were twelve 
treated for prostate cancer, which does not correspond with demographic characteristics. Therefore, 
case-control matching was performed. 
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Some controls were conducted to confirm the generalizability of our results. First, the recent G8 result 
enables a correct estimation of trial patients’ fitness which is decisive for the interpretation of study 
results. More importantly, based on five crucial parameters, cases have been matched to control patients 
included in the oncogeriatric database. This case-control matching corrects for any trial under- or 
overrepresentation and ensures a correct representation of the real life oncology population. Moreover, 
the proportions of G8- and G8+ older patients included in the matched control group resemble closely 
the proportions of older patients with cancer included in the oncogeriatric database, which suggests that 
the matched controls are representative for the older patients with cancer in a real life oncology setting. 
Furthermore, demographic and clinical characteristics of the excluded patients with CGA result 
available (N=48) have been analysed. An independent sample t-test and Exact Pearson Chi-Square test 
showed there was no statistically significant difference between the excluded patients and the cases, 
neither for the matching criteria gender (p=0.5), age (p=0.6), tumour type (p=0.1), tumour stage (p=0.5), 
and treatment intent (p=0.8), nor for the number of G8+ versus G8- cases (p=0.2) (data not shown). The 
majority of the excluded patients (56.1%) had a fit profile. However, this G8 result was obtained more 
than 6 months before or after trial inclusion, therefore no conclusions can be drawn. 
To the best of our knowledge, we are the first to publish quantitative data on the proportion of vulnerable 
older patients with cancer included in clinical trials, in comparison to the real life population. We believe 
our data support the inclusion of G8 and/or CGA for oncogeriatric patients enrolled in clinical trials to 
improve adequate patient selection, risk stratification, and efficacy and safety evaluation. Agreement on 
a (more or less) uniform and straightforward evaluation of the fitness of the older population such as the 
G8 could contribute to better characterized patient populations, avoiding selection bias caused by the 
heterogeneity of the population. 
In conclusion, this case-control study provides evidence for the hypothesis that older patients included 
in phase II or III oncology trials are significantly fitter than the real life oncology population. Integration 
of the G8 screening tool and/or CGA in future cancer clinical trials could enable stratification according 
to this parameter and allow subgroup analysis. New approaches to tackle the underrepresentation of 
vulnerable older patients with cancer in clinical trials are needed such as DECs in early phase trials and 
extra cohorts in later phase trials. This will broaden the application and interpretation of trial results. 
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